Login
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

lyell.com

What Do They Do?

Develops cancer therapy candidates made from patients’ own immune cells, including engineered T-cell therapies for blood cancers and solid tumors.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $274.4M in FY2025.

Operating income, FY2025
−748344% of revenue
▲ +25% (Loss) vs FY2024 (−$358.8M, −588123%)
Net income, FY2025
−762356% of revenue
▲ +20% (Loss) vs FY2024 (−$343M, −562285%)
Free cash flow, FY2025
−418900% of revenue
▲ +7% (Loss) vs FY2024 (−$162.9M, −266980%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −80%
vs $15K in Q3 FY2025
Net income
▼ −17% (Loss)
vs −$38.8M in Q3 FY2025

Shrinking. Revenue fell 100% in 4 years, from $10.7M in FY2021 to $36K in FY2025, about 76% a year.

A blood-cancer lead The older report centered on proprietary T-cell reprogramming and a pipeline for solid tumors across CAR, TIL and TCR approaches. The latest report centers on CAR T-cell candidates for blood cancers, led by ronde-cel, alongside solid-tumor programs.

Who Do They Compete With?

Competes with Agenus, Akeso, Arcellx, Allogene Therapeutics, Arsenal Biosciences, AstraZeneca, Autolus Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Gilead Sciences, Immunocore Holdings, Johnson & Johnson, Nanjing Legend Biotech, Novartis, Pfizer, Poseida, F. Hoffmann-La Roche, Summit Therapeutics, Amgen, and AbbVie

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support